Group 1: n=30: infraclavicular patient-controlled perineural bupivacaine (0.5 % MARCAIN
flacon, Astra Zeneca, Sweden) (0.1 % bupivacaine, bolus dose 5 ml, infusion rate 5 ml/h, lockout time 1 hour)(14).
Sim and Tan applied intradermal injection of MB and Marcain solution in the treatment group, compared to intradermal injection of Marcain and saline solution in control group .
used intradermal injection of MB, Marcain, and adrenaline solution in 49 refractory pruritus ani (RPA) patients to assess the effectiveness of the MB in reducing symptom score [9,10].
Next, 2 mL of hyperbaric bupivacaine hydrochloride (Marcain
Heavy 0.5%; AstraZeneca[R], London, UK) was given to patients in the USA group in the lateral decubitus position, after regional sterilisation, through the selected intervertebral space (randomly L4-L5 or L3-L4 segment) using a 25-G Quincke spinal injector (B.
In study done by Hannu Paaajanen local infiltration anaesthesia was a 1:1 mixture of bubivacaine (Marcain
5mg/ml, Astra Zeneca) and Citanest-adrenalin (10mg/ml+5gg/ml, Astra Zeneca) with an average total volume of 40-50ml.
An experimental study of axonal degeneration and barrier damage after intrafascicular injection or topical application of bupivacaine (Marcain
09.46 After successfully locating the dura and injecting Marcain
Heavy 0.5% (bupivacaine) to induce an effective block, the patient was asked to lie down on the operating table.
For induction of analgesia, an intrathecal dose of plain 2 to 2.5 mg of ropivacaine (Naropin, AstraZeneca, Sweden) or bupivacaine (Marcain
, AstraZeneca, Sweden) was used together with fentanyl 10 to 15 [micro]g.
With the patient in the sitting position, due consideration needs to be given to the specific gravity of the heavy marcain solution.
With the addition of glucose to the heavy marcain solution, this gives it a specific gravity of 1.024.
Astra Zeneca UK Limited 2005 Marcain
Polyamp Steripack SPC Available from: www.medicines.org.uk [Accessed 8 July 2008]